Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients

Published:2015-09-10 Issue:11 Volume:17 Page:1085-1092
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

McInnes G.¹,Evans M.²,Del Prato S.³,Stumvoll M.⁴,Schweizer A.⁵,Lukashevich V.⁶,Shao Q.⁶,Kothny W.⁵

Affiliation:

1. Institute of Cardiovascular and Medical Sciences; University of Glasgow; Glasgow UK

2. University Hospital Llandough; Cardiff UK

3. Department of Clinical and Experimental Medicine; University of Pisa; Pisa Italy

4. Division of Endocrinology; University Hospital Leipzig; Leipzig Germany

5. Novartis Pharma AG; Basel Switzerland

6. Novartis Pharmaceuticals Corporation; East Hanover NJ USA

Funder

Novartis Pharma AG

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12548/fullpdf

Reference70 articles.

1. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005;Preis;Circulation,2009

2. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies;Sarwar;Lancet,2010

3. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes;Nissen;N Engl J Med,2007

4. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a double-blind, randomized, pioglitazone-comparative study;Kendall;Diabetes Care,2006

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expert Consensus on Dipeptidyl Peptidase-4 Inhibitor-Based Therapies in the Modern Era of Type 2 Diabetes Mellitus Management in India;Cureus;2024-06-05

2. Patient-Driven Solutions: Integrating Vildagliptin and Dapagliflozin in Diabetes Management;International Journal of Diabetes and Endocrinology;2024-05-10

3. Critical role of miR-21/exosomal miR-21 in autophagy pathway;Pathology - Research and Practice;2024-05

4. Vildagliptin Sustained-release and Dapagliflozin Fixed-dose Combination in the Management of Type 2 Diabetes Mellitus: A Comprehensive Review;International Journal of Diabetes and Technology;2024-04

5. Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective;Clinical Medicine Insights: Endocrinology and Diabetes;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3